BioCryst Pharmaceuticals, Inc. (BCRX) Shares Sold by Legal & General Group Plc
Legal & General Group Plc lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,486 shares of the biotechnology company’s stock after selling 241 shares during the period. Legal & General Group Plc’s holdings in BioCryst Pharmaceuticals were worth $146,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of BCRX. FMR LLC increased its stake in shares of BioCryst Pharmaceuticals by 97.5% in the first quarter. FMR LLC now owns 1,456,885 shares of the biotechnology company’s stock valued at $12,238,000 after buying an additional 719,162 shares in the last quarter. Wellington Management Group LLP acquired a new position in BioCryst Pharmaceuticals during the first quarter valued at $1,700,000. Principal Financial Group Inc. increased its position in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 45 shares during the period. Emory University acquired a new position in BioCryst Pharmaceuticals during the first quarter valued at $3,153,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in BioCryst Pharmaceuticals during the first quarter valued at $337,000. Institutional investors own 84.72% of the company’s stock.
Shares of BioCryst Pharmaceuticals, Inc. (BCRX) traded down 1.259% during mid-day trading on Wednesday, hitting $4.315. The stock had a trading volume of 81,519 shares. BioCryst Pharmaceuticals, Inc. has a 12-month low of $3.75 and a 12-month high of $9.25. The stock’s market capitalization is $347.05 million. The stock’s 50-day moving average price is $5.27 and its 200-day moving average price is $6.25.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The firm had revenue of $3.10 million during the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the prior year, the company earned ($0.22) EPS. BioCryst Pharmaceuticals’s quarterly revenue was down 35.4% on a year-over-year basis. On average, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post ($0.73) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/biocryst-pharmaceuticals-inc-bcrx-shares-sold-by-legal-general-group-plc/1494876.html.
Several equities analysts recently weighed in on BCRX shares. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Saturday, May 6th. Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Monday, May 1st. ValuEngine lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, May 19th. Finally, BidaskClub upgraded BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $8.00.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.